Integrated molecular and pharmacological characterization of patient derived xenografts from bladder and ureteral cancers identifies new potential therapies
Lang H. et al., 2022. Frontiers in Oncology, 12
Recurrent activating mutations of PPAR γ associated with luminal bladder tumors
Rochel N. et al., 2019. Nature Communications, 10(1):253.
An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers
Mahe M. et al., 2018. EMBO Molecular Medicine, 10(4):e8163
Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma
Lang H. et al., 2016. Oncotarget, 7:59336-59359
